The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people
Open accessAbstract
Aims: The benefit an individual can expect from preventive therapy varies based on risk-factor burden, competing risks, and treatment duration. We developed and validated the LIFEtime-perspective CardioVascular Disease (LIFE-CVD) model for the estimation of individual-level 10 years and lifetime treatment-effects of cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Methods and results: Model development was conducted in the Multi-Ethnic Study of Atherosclerosis (n = 6715) using clinical predictors. The model consists of two complementary Fine and Gray competing-risk adjusted left-truncated subdistribution hazard functions: one for hard cardiovascular disease (CVD)-events, and one for non-CVD mortality. Therapy-effects were estimated by combining the functions with hazard ratios from preventive therapy trials. External validation was performed in the Atherosclerosis Risk in Communities (n = 9250), Heinz Nixdorf Recall (n = 4177), and the European Prospective Investigation into Cancer and Nutrition-Netherlands (n = 25 833), and Norfolk (n = 23 548) studies. Calibration of the LIFE-CVD model was good and c-statistics were 0.67–0.76. The output enables the comparison of short-term vs. long-term therapy-benefit. In two people aged 45 and 70 with otherwise identical risk-factors, the older patient has a greater 10-year absolute risk reduction (11.3% vs. 1.0%) but a smaller gain in life-years free of CVD (3.4 vs. 4.5 years) from the same therapy. The model was developed into an interactive online calculator available via www.U-Prevent.com. Conclusion: The model can accurately estimate individual-level prognosis and treatment-effects in terms of improved 10-year risk, lifetime risk, and life-expectancy free of CVD. The model is easily accessible and can be used to facilitate personalized-medicine and doctor–patient communication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Earlier onset of metabolic risk factors is associated with increased risk for CVD and mortality, motivating the timely identification and treatment of risk factors.47–49”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [47]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In general, these studies found that GLP-1–based therapies would not be cost-effective compared with usual care, especially when used as first-line therapy.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [47]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast, GLP-1 RAs appear to primarily reduce the risk of atherosclerotic events, such as MI and stroke.45–48”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [47]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 5,932
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citation
Research works printed but not linked: 1
- 2007, Risk Estimation and the Prevention of Cardiovascular Disease. A National Clinical Guideline
Cited by
Sorted by citations
Items 101–119 of 119
Lijing Lin, A., Poppe, K., Wood, A., Martin, G. P., Peek, N. B., & Sperrin, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1824359/v2
Commentary to "How to Treat Peripheral Arteriovenous Malformations"
Candela, E. (2023) · Angiología · doi:10.20960/angiologia.00486
Actualización y validación del riesgo cardiovascular
Cuende, J. I. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.05.004
Update and validation of cardiovascular risk
Cuende, J. I. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.06.002
Will you take the opportunity to assess and manage cardiovascular risk?
Patel, R. S. (2024) · Trends in Urology & Men s Health · doi:10.1002/tre.964
Long-Term Mortality Prediction with Pooled Cohort Equations: Implications for Lipid-Lowering TherapyPreprint
Ma, Z., Moran, L. N., & Shirani, J. (2024) · medRxiv · doi:10.1101/2024.04.05.24305406
PERFIL EPIDEMIOLÓGICO DO LABORATÓRIO DE HEMODINÂMICA DO HOSPITAL SÃO LUCAS
Brustolin, L. M., Rodrigues, M. B., Barbosa, R. V., Michelon, I. C., & de Almeida, R. M. D. S. S. A. (2024) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.61164/rmnm.v6i1.2405
Ma, Z., Moran, L. N., & Shirani, J. (2024) · Cureus · doi:10.7759/cureus.72856
Pedicino, D., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf398
Kornelius, E., Hu, T., Chiao, C., Hwang, J., & Chan, T. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200537
Livingstone, S. J., Morales, D. R., Fleuriot, J., Donnan, P. T., & Guthrie, B. (2024) · Figshare · doi:10.6084/m9.figshare.26582516
The year in cardiology: Cardiovascular prevention
Ray, K. K., Laufs, U., Cosentino, F., Lobo, M. D., & Landmesser, U. (2019) · Srce i krvni sudovi · doi:10.5937/siks1904184r
Cardiovascular health metrics among an Iranian population: insights from life’s essential 8
Kazemi, T., Jafarizadeh, R., Bizhaem, S. K., Bijari, B., & Karbasi, S. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05201-w
Bongaerts, V. A. M. C., Vos, R. C., Hageman, S. H. J., Redekop, K., Dorresteijn, J. A. N., Numans, M. E., & van Os, H. J. A. (2026) · BMJ Open · doi:10.64898/2026.02.13.26345729
Self-citation29317 Spezielle Begutachtungsfragen aus der Praxis
(2026) · De Gruyter eBooks · doi:10.1515/9783111591360-017
Could Malnutrition Be a Potential Parameter for Cardiac Risk Assessment in Older Adults?
Özgün, Ö., Baş, A. O., Cengiz, D., Kayabaşı, C., Uyar, A., Turhan, O., Nacar, İ. A., Çıkın, C., Pehlivan, M., Balcı, C., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062135
Kerniss, H., Rühle, S., Clemens, K., Hanses, U., Schmucker, J., Osteresch, R., Fach, A., Hambrecht, R., & Wienbergen, H. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-02902-w
Otiman, G., Rosca, C. I., Nisulescu, D. D., Mahmoud, A., Pah, A.-M., Velimirovici, D. E., Ples, C., & Stoichescu-Hogea, G. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145627
Metadata
- Authors
- Jaspers, N. E. M., Blaha, M. J., Matsushita, K., van der Schouw, Y. T., Wareham, N. J., Khaw, K.-T., Geisel, M. H., Lehmann, N., Erbel, R., Jöckel, K.-H., van der Graaf, Y., Verschuren, W. M. M., Boer, J. M. A., Nambi, V., Visseren, F. L. J., & Dorresteijn, J. A. N.
- Affiliations
- University Medical Center Utrecht (NL)
- Johns Hopkins University (US)
- Julius Center for Health Sciences, University Medical Center Utrecht , Heidelberglaan 100, 3584 CX Utrecht, Netherlands
- University of Cambridge (GB)
- Essen University Hospital (DE)
- National Institute for Public Health and the Environment (NL)
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- Visseren, Frank L J
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-18
- Volume
- 41
- Issue
- 11
- Pages
- 1190-1199
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC7229871
- OpenAlex
- W2946535940
- Semantic Scholar
- 368b09086d76ea5df90cd8c033f6fe36aba73100
- Cited by
- 120
- References
- 34
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 18 · 2023: 15 · 2022: 20 · 2021: 24 · 2020: 14 · 2019: 5
- FWCI
- 14.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Rivm Repository (Netherlands National Institute for Public Health and the Environment) (submittedVersion)
- Rivm (National Institute for Public Health and the Environment) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Apollo
- Funders
- Netherlands Heart Foundation (2016T026, HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169)
- National Heart, Lung, and Blood Institute (UL1-TR-000040, UL1-TR-001420)
- NCATS
- National Institutes of Health (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I)
- ‘Europe Against Cancer’ programme of the European commission
- Dutch ministry of health, Welfare and Sports
- Netherlands Organization for Research and Development
- World Cancer Research Fund
- Medical Research Council
- Heinz Nixdorf Foundation
- German Ministry of Education and Science
- BMBF
- Deutsches Zentrum für Luft- und Raumfahrt
- German Research Council Assessment (SI 236/8-1, SI 236/9-1)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Keywords
- cardiovascular risk prediction, cholesterol lowering, blood pressure reduction, antithrombotic therapy, smoking cessation, prophylaxis, competing risks, absolute risk reduction, personalized medicine, physician-patient communication, online risk calculator
- MeSH terms
- Aged, Blood Pressure, Cardiovascular Diseases, Cholesterol, Fibrinolytic Agents, Humans, Middle Aged, Netherlands, Prospective Studies, Risk Factors, Smoking Cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
